Celgene Corp said on Tuesday that in a late-stage clinical trial, patients with metastatic melanoma who took its drug Abraxane lived for a longer period without getting worse than those who received the chemotherapy dacarbazine.
ShareSaturday, November 3, 2012
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment